Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
about
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewHIV-Host Interactions: Implications for Vaccine DesignPoxvirus vectors as HIV/AIDS vaccines in humansA global approach to HIV-1 vaccine developmentProspective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewEvaluation of locally established reference intervals for hematology and biochemistry parameters in Western KenyaLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaMapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step studyIn vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialContextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials.Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.Human immunodeficiency virus vaccine trialsHIV-1 Vaccine Trials: Evolving Concepts and DesignsCLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.Novel directions in HIV-1 vaccines revealed from clinical trialsRepeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitPhase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateSafety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya.Bayesian spatial semi-parametric modeling of HIV variation in Kenya.Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIVCharacterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c miceA phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Fate of TLR-1/TLR-2 agonist functionalised pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro.Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infantsRole of cell signaling in poxvirus-mediated foreign gene expression in mammalian cellsHIV DNA Vaccine: Stepwise Improvements Make a Difference.Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.A pilot study to determine the normal haematological indices for young Malawian adults in Blantyre, Malawi.Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
P2860
Q26700078-02F9E7B6-D2EA-4F18-B221-23CD690759E9Q26765966-20A4E4E0-CAB6-4444-9356-D1198099CE11Q26995078-9A3E6711-0CDC-41F2-8E15-0A4D161441EEQ27024614-504BA431-A700-40EC-9719-3612A1A9493FQ28485174-BFABD0AB-E20B-48D7-9E73-C5CFA3C71EBEQ28546175-08EBAAD6-B56B-42F8-A329-87DFE1956E19Q28654629-D10983B1-5AEB-4839-9AF5-642855C60A21Q28743767-52060D8F-2836-4465-884B-F53F93DC81C2Q28744555-27C984EC-83EA-4603-904D-AA75AC50B08AQ28972526-5CBE21F9-6108-4FBB-B60E-6F15CF7B59BCQ30148638-3CE7D350-2AFC-425E-8510-6D0DB8E30F34Q30375160-8AF11D14-4196-46B1-934D-52A9E8B2D4ADQ30375979-4BF78A56-2ED9-46F4-B0E2-CC9BCE0D0673Q30378897-E2B7BF2C-1119-4C32-A8CD-8FA115671AA7Q30399174-1CF679AF-8A88-436C-80EF-BA129C02650DQ30424366-A74EEAEC-6A45-4896-94EF-3048CFB2A010Q30425520-2C0C1767-A478-42F4-99F8-5BC57133DB69Q33406262-C30F239F-E084-4326-AA22-74897CA34A9DQ33645528-384AA2E8-CD98-4BC4-86AC-5BC97A3A0E37Q33698152-C3723435-7484-454D-B9E5-1AD7EF01A39FQ33749950-ADC7D711-0169-4841-8F13-267EA4A7E508Q33875160-C363A75B-0A4D-4330-A7A0-CE6A746848E3Q33945504-EF9B8523-CA38-45B1-8893-5489AED60434Q33952398-C7B9128C-45B6-48C2-A0E4-9D774D57AF01Q34099837-FBF382F9-085E-467C-AFE7-5D29EEA32986Q34309830-6186F336-A84F-43EB-B81A-59B18497557CQ34514374-AE2C61EC-FB10-4B87-9823-72434C9FE226Q34592940-80AABBBB-1DAA-4415-B111-13F6535B966EQ34593969-7B6636A7-3CC8-4EDC-946F-01A3044CFC92Q34729962-773AF692-BD2D-47E0-B20D-2E3BD40558D6Q34960453-418A56DA-210F-44EF-91FE-F0FF7D15A3D8Q34989509-0EB96FC1-89B4-4124-AB48-4D598C22119EQ35036289-A3CA3DCD-59A9-4A2E-BE1B-5F1AC528F34AQ35292450-86F66724-07B8-45D6-B7BD-B19C01C3A3A9Q35826742-14A68597-6BA4-40E2-A3AF-D5EA42BAA1C5Q36397581-791E6EB5-640A-4064-A6CA-CCC3A88F2D1FQ36397770-05C915EE-BDDE-4ADC-84F2-202E60BB26C6Q36697992-48B6AE73-7918-48CE-9D53-C3FB2E2990DCQ37333743-F5FEC28B-2F94-4291-83AF-74320C52AB98Q37643731-82A4C269-BA81-432D-A3E8-6F8D86C48D1F
P2860
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Safety and immunogenicity of r ...... MVA) in humans in East Africa.
@en
type
label
Safety and immunogenicity of r ...... MVA) in humans in East Africa.
@en
prefLabel
Safety and immunogenicity of r ...... MVA) in humans in East Africa.
@en
P2093
P50
P1433
P1476
Safety and immunogenicity of r ...... MVA) in humans in East Africa.
@en
P2093
Andrew McMichael
Andrew Muluubya
Bruce Johnson
Burc Barin
Carol Konde
Carol Smith
Claudia Schmidt
Emmanuel Mugisha
Farah Bashir
Frederick N Nakwagala
P304
P356
10.1016/J.VACCINE.2008.02.071
P407
P577
2008-03-31T00:00:00Z